Jakel shared the story of a young mother who had been deemed difficult and “in denial” by other staff due to her rejecting ...
Despite these totals, the long-term trend in cancer mortality reflects significant progress. As of 2023, the age-adjusted cancer death rate had dropped by 34% from its peak in 1991, averting an ...
The FDA has accepted and granted priority review to a supplemental biologics license for datopotamab deruxtecan-dlnk ...
The advantage of MCED testing is its potential to identify cancers at earlier, more treatable stages; detecting cancer even ...
An advocate is not the same as a health care proxy who is assigned to speak for a patient on their advanced directives.
She noted that she became a better nurse under his mentorship, thanks to the “wisdom and skills he instilled in [her].” His ...
The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
From FDA actions to new standard-of-care potential, the breast cancer treatment arsenal continues to expand. This week’s news ...
Recent clinical developments in the treatment of platinum-resistant ovarian cancer (PROC) have introduced several novel therapeutic classes, including selective glucocorticoid receptor antagonists, ...
The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL. The FDA approved a larger vial size of 375 mg/75 mL for nelarabine (Arranon) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results